SCHEMBL5311428

SCHEMBL5311428

Cc1ccc2ccc3c(C#N)cc(C(=O)c4ccccc4)n3c2c1

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ FNTA P49354 4/20 0.43
▸ FNTB P49356 4/20 0.43
▸ MEN1 O00255 4/20 0.42
▸ KMT2A Q03164 4/20 0.42
▸ L3MBTL1 Q9Y468 2/20 0.42
▸ PTPN1 P18031 2/20 0.42
▸ CDC25A P30304 2/20 0.42
▸ DUSP3 P51452 2/20 0.42
▸ CMA1 P23946 1/20 0.39
▸ MAPK1 P28482 2/20 0.39
▸ MAPT P10636 1/20 0.39
▸ CRHBP P24387 1/20 0.39
▸ CRHR2 Q13324 1/20 0.39
▸ TSHR P16473 1/20 0.38
▸ POLB P06746 1/20 0.38
▸ PKM P14618 1/20 0.37
▸ NPSR1 Q6W5P4 1/20 0.36
▸ ALDH1A1 P00352 1/20 0.36
▸ HTT P42858 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5959296 0.93 MEN1 (0.42) FNTAFNTBMEN1KMT2AL3MBTL1
SCHEMBL5309491 0.88 LMNA (0.41) MEN1KMT2AL3MBTL1MAPK1MAPT
SCHEMBL5959209 0.88 MAPK1 (0.44) FNTAFNTBMEN1KMT2AL3MBTL1
SCHEMBL5310989 0.87 PTPN1 (0.44) FNTAFNTBL3MBTL1PTPN1CDC25A
SCHEMBL5959267 0.86 MEN1 (0.43) MEN1KMT2APTPN1CDC25ADUSP3
SCHEMBL5257352 0.81 PTPN1 (0.40) PTPN1CDC25ADUSP3MAPK1
SCHEMBL5959279 0.81 MEN1 (0.40) FNTAFNTBMEN1KMT2APTPN1
SCHEMBL5315747 0.80 CYP3A4 (0.43) KMT2AMAPTHTT
SCHEMBL5313502 0.78 LMNA (0.41) MEN1KMT2APTPN1CDC25ADUSP3
SCHEMBL5959251 0.78 FNTA (0.44) FNTAFNTBMEN1KMT2APTPN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7135480-B2 Anticarcinogenic agents; colon, lymphoma, lung, prostate and breast cancers CYTOVIA, INC. (US) 2006-11-14 — — US claimed
US-20050014759-A1 Substituted 1-benzoyl-3-cyano-pyrrolo [1,2-a] quinolines and analogs as activators of caspases and inducers of apoptosis CYTOVIA, INC. 2005-01-20 — — US claimed
EP-1578424-A4 SUBSTITUTED 1-BENZOYL-3-CYANO-PYRROLO 1,2-A| QUINOLINES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS CYTOVIA INC (US) 2007-08-08 — — EP disclosed
US-7135480-B2 Anticarcinogenic agents; colon, lymphoma, lung, prostate and breast cancers CYTOVIA, INC. (US) 2006-11-14 — — US disclosed
EP-1578424-A2 SUBSTITUTED 1-BENZOYL-3-CYANO-PYRROLO 1,2-A] QUINOLINES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS Cytovia, Inc. (US) 2005-09-28 — — EP disclosed
US-20050014759-A1 Substituted 1-benzoyl-3-cyano-pyrrolo [1,2-a] quinolines and analogs as activators of caspases and inducers of apoptosis CYTOVIA, INC. 2005-01-20 — — US disclosed
WO-2004055163-A2 SUBSTITUTED 1-BENZOYL-3-CYANO-PYRROLO[1,2-A]QUINOLINES CYTOVIA, INC. (US) 2004-07-01 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050014759-A1 Substituted 1-benzoyl-3-cyano-pyrrolo [1,2-a] quinolines and analogs as activators of caspases and inducers of apoptosis CASP3, CASP7, CASP1 FNTA 4636/4885FNTB 4626/4885MEN1 2503/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback